Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Alendronate-induced hepatocellular lesion].

C de La Serna Higuera1, A Pérez Villoria, S Rodríguez Gómez

  • 1Unidad de Digestivo. Hospital Virgen de la Concha. Zamora.

Gastroenterologia Y Hepatologia
|June 20, 2001
PubMed
Summary

Bisphosphonate-induced liver injury is rare. This case report details a 76-year-old woman with osteoporosis who experienced elevated liver enzymes after starting alendronate, which resolved upon discontinuation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Computed tomography characteristics of isolated caecal ischaemia].

Radiologia·2012
Same author

Cytomegalovirus ileitis in an immunocompetent patient.

Revista espanola de enfermedades digestivas·2011
Same author

[Radiation colitis].

Revista espanola de enfermedades digestivas·2009
Same author

[Colonic preparation with polyethylene glycol, hypophosphatemia and acute confusional syndrome].

Gastroenterologia y hepatologia·2005
Same author

Efficacy and safety of argon plasma coagulation for the treatment of hemorrhagic radiation proctitis.

Revista espanola de enfermedades digestivas·2004
Same author

Complete spontaneous submucosal dissection of the sigmoid colon.

Endoscopy·2004

Area of Science:

  • Pharmacology
  • Hepatology
  • Metabolic Bone Disease

Background:

  • Bisphosphonates are first-line pharmacotherapy for osteoporosis and other metabolic bone diseases.
  • Bisphosphonate-induced hepatotoxicity is an exceptionally rare adverse effect.
  • Alendronate is a commonly prescribed bisphosphonate for osteoporosis.

Observation:

  • A 76-year-old female patient with osteoporosis was treated with alendronate.
  • Routine laboratory tests after three months showed significantly elevated transaminase levels.
  • Liver function normalized within six weeks of discontinuing alendronate.

Findings:

  • The patient's elevated transaminases were likely attributable to alendronate.
  • This case highlights a rare instance of bisphosphonate-induced liver injury.

Related Experiment Videos

  • Possible pathogenic mechanisms for alendronate hepatotoxicity are discussed.

    • Implications:

    • Clinicians should consider monitoring liver function in patients on bisphosphonate therapy, especially with prolonged use.
    • Early recognition and withdrawal of the offending agent are crucial for managing drug-induced liver injury.
    • Further research into the mechanisms of bisphosphonate hepatotoxicity may inform safer prescribing practices.